Nationality German | ||
 | ||
Known for Novel drug candidates for diabetes and obesity based on gut-brain signals Notable awards Erwin Schrödinger Preis (2014); Paul Martini Prize (2014); Outstanding Scientific Achievement Award, American Diabetes Association (2011); Scientific Achievement Award, The Obesity Society (2007) Institutions | ||
Matthias tsch p alexander von humboldt professorship 2012 en
Matthias H. Tschöp (born April 7, 1967) is a German physician and scientist best known for novel therapeutic approaches to diabetes and obesity based on dissecting gut-brain communication. He is Alexander-von-Humboldt Professor and Chair of Metabolic Diseases at Technische Universität München. In addition, he serves as Director of Biomedicine at Helmholtz Pioneer Campus, Research Director of the Helmholtz Diabetes Center and Director of the Institute for Diabetes and Obesity at Helmholtz Zentrum München. Matthias Tschöp also holds an Adjunct Professorship at Yale University and was elected into the German National Academy of Sciences Leopoldina in 2013.
Contents
- Matthias tsch p alexander von humboldt professorship 2012 en
- Der mediziner prof dr matthias tsch p
- Career and research
- Awards and recognition
- References
Der mediziner prof dr matthias tsch p
Career and research
Matthias Tschöp obtained an M.D. from the Ludwig Maximilian University of Munich (1993) where he worked as a clinician (1994-1998) in neuroendocrinology before accepting a research fellowship at the Eli Lilly Discovery Research Laboratories (1999-2002) and leading a research team at the German Institute of Human Nutrition (Potsdam/Nuthetal 2002-2003). He served as a Professor of Endocrinology and Diabetes at the Metabolic Diseases Institute of the University of Cincinnati (2003-2009), before being named the Arthur Russell Morgan Endowed Chair of Medicine, and Research Director of the Metabolism Center of Excellence for Diabetes and Obesity at the University of Cincinnati (2009-2011).
Early in his career, Tschöp reported on the orexigenic, adipogenic, and metabolic effects of ghrelin and its secretory control by nutrients, which has had a major influence on human obesity and diabetes research. His corresponding publication in Nature is among today’s most frequently cited metabolism research papers. It added a fundamental pathway to the current model of body weight and glucose control and established novel drug targets for metabolic diseases. Tschöp went on to further dissect gut-brain communication pathways, based on GI-hormone signaling and lessons from unraveling the molecular underpinnings of gastric bypass surgery.
Together with his close collaborator Richard DiMarchi (Indiana University) he discovered and validated novel gut hormone co-agonist peptides, which simultaneously target several neuroendocrine receptors and efficiently reduce body weight and improve glucose tolerance. Several of these compounds are now in clinical trials for the treatment of diabetes and obesity. Tschöp and DiMarchi more recently went on to discover and validate another class of drug candidates by engineering peptide to deliver steroid/small molecules to selected cell populations.
Awards and recognition
